


R&D systems™
by biotechne

Targeted Protein Degradation & *Induced Proximity*

Product Guide / Edition 8




Induced Proximity & Targeted Protein Degradation

The R&D Systems™ brand, by Bio-Techne, offers a unique portfolio of high-quality reagents, instruments and services for researchers working in the rapidly growing field of Targeted Protein Degradation (TPD) and Induced Proximity. Our bespoke range of tools and reagents includes small molecule Protein Degraders; TAG Degradation Platform, including dTAG, aTAG, BromoCatch™ and BromoTag® Degraders; Degradation Building Blocks; Assays for Protein Degradation; Ubiquitin-Proteasome System Proteins and Assays; and Custom Degradation Services.



Target Exploration & Validation



Assays for Targeted Protein Degradation



Degradation Design & Synthesis



Induced Proximity Tools



Learn More About Workflow Solutions for TPD Research
Scan the QR code or visit rndsystems.com/research-area

BromoTag® is a registered trademark of the University of Dundee and is used under license.

Contents

Introduction to Induced Proximity	04
Target Exploration and Validation	05
Mechanistic Controls for Degradation Development	08
TAG Degradation Platform	09
BromoCatch™ Self Labeling Protein Tag Platform	11
Degradation Design & Synthesis	12
Assays for Targeted Protein Degradation	13
Target Engagement & Ternary Complex Formation	14
Simple Western: A Step Beyond Traditional Western Blots	15
Leo System	16
Proteins for in vitro Ubiquitination Assays	17
How Has This Degradation Affected My Cells?	18
Induced Proximity Tools	20

Introduction to Induced Proximity

Induced proximity employs the use of two ligands covalently joined by a linker to bring two proteins, a target protein of interest (POI) and an effector, into close proximity. The induced proximity of POI and effector leads to an alteration to the POI, triggering a biological response. The POI can undergo a variety of changes including post-translational modification, degradation, autophagy, stabilization, dimerization and cellular shuttling/ protein redistribution.

Targeted protein degradation utilizes heterobifunctional small molecule Degraders (e.g. PROTAC® molecules) to bind the POI and recruit an E3 ligase to form a ternary complex. This initiates the ubiquitination of the POI and its subsequent destruction by the proteasome. There are a number of significant benefits to using this technology. Efficient and highly selective protein knock-down can be achieved both in vitro and in vivo. Degraders act catalytically by repeatedly engaging and directing the ubiquitination of the POI and can therefore be used at very low doses to achieve sustained knock-down. The R&D Systems brand offers a range of products and services to support your research in this field.

FIGURE 1
Targeted Protein Degradation via an Induced Proximity Mechanism of Action




Figure 1 The catalytic mode of induced proximity. The effector complex is brought into close proximity to the POI. For example the POI is brought into proximity to an E3 ubiquitin ligase by an effector such as cereblon, the POI is polyubiquitinated and is then recognized by the proteasome and subsequently degraded.

PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Target Exploration and Validation

Protein Degraders

R&D Systems targeted protein degradation has pioneered commercialization of tool Protein Degraders to make them available to the research community. They provide an easy-to-use alternative to genetic manipulation for investigating phenotypic consequences of target protein knockdown. A selection of our growing range is provided in the table below, and the full range is available through our website: randsystems.com/research-area/targeted-protein-degradation

R&D Systems antibodies is also constantly developing new antibodies to help you evaluate the efficacy of your degrader. The antibodies listed in the table below are suitable for Western Blot and most have been validated for our Simple Western instruments (more information on gel-free, blot-free and hands-free Western Blot can be found on page 15).

FIGURE 2




Figure 2. An overview of TPD targets degraded by the proteasome.

TABLE 1
Protein Degraders Catalog

Target Protein	Product Name	Catalog #	Negative Control Available	Simple Western Validated Antibody	Western Blot Validated Antibody
α-Synuclein	α-Synuclein Degradar 2b	8040			
Adrenergic Receptors	α1A-AR Degradar 9c	7278			MAB10298
AKT	MS 143	8081			
ALK	TL 13-112	6745	Y		
	TL 13-12	6744	Y	AF4210	AF4210
Androgen Receptor & Mutants	ARCC 4	7254	Y	MAB58762	MAB58762
	AZ 3137	8833			
ATTEC	PDE6 ATTEC 12C	8824			
Aurora A	JB 300	7837		AF3295, NBP1-51843	AF3295, NBP1-51843
BCR-Abl	GMB 475	7265			
	ARV 771	7256			
	AT 1	6356			
	dBET1	6327			
BET Bromodomains: BRD2, BRD3, BRD4	dBET6	6945			
	MZ 1	6154	Y		
	SIM 1	7432	Y		
	HHP 9	7828			

TABLE 1
Protein Degraders Catalog (Continued)

Target Protein	Product Name	Catalog #	Negative Control Available	Simple Western Validated Antibody	Western Blot Validated Antibody
BRD9	dBRD9	6606		BRD9 - NBP3-14730	BRD9 - NBP3-14730
	dBRD9-A	6943		NBP3-14730	NBP3-14730
BRD7/9	VZ 185	6936	Y	BRD7	BRD7- NBP1-28727
BRAF & Mutants	CG 858	7427	Y	AF3424	AF3424
	SJF 0628	7463	Y		
	CST 905	7745			
BTK	DD 03-171	7160		MAB5807, NBP2-02472	
	NX 5948	8856			
	NX 2127	8951			
β-Catenin	xStAx-VHLL	7298		AF1329, NBP1-54467	AF1329, NBP1-54467
CDK2	CPS2	7800			
CDK6	BSJ-03-123	6921			NBP1-87262
CDK4/6	BSJ-03-204	6938		CDK-4 AF5254, NBP1-31308	CDK-4 AF5254, NBP1-31308
	HEMTAC 26	7940			
CDK8	JH-XI-10-02	7304			NBP2-92972
CDK9	THAL SNS 032	6532			NBP2-15848, NBP3-15345
CDK9-cyclin T1 Complex	LL-K9-3	7813			
CDK12	BSJ-4-116	7528			
cMET	SJF 8240	7266			AF276, MAB5694
CRBN	CRBN-6-5-5-VHL	6948		NBP1-91810	NBP1-91810
	CRBN PROTAC® 14a	7219			
Cyclin D1	MS 28	8076			
EGFR & Mutants	Gefitinib-based PROTAC® 3	7258		AF231	AF231
	MS 154	7395	Y		
	MS 39	7397	Y		
	SJF 1521	7261			
	SJF 1528	7262			
	SJF 0661	7464			
EP300	JQAD1	7682		AF3789	AF3789
ERK5	PPM-3	8116			
Estrogen Receptor	SNIPER(ER)-87	7120		AF5715, MAB57151	AF5715, MAB57151
FAK	FC 11	7306		AF4467, MAB4467	AF4467, MAB4467
	GSK 215	7818			

TABLE 1
Protein Degraders Catalog (Continued)

Target Protein	Product Name	Catalog #	Negative Control Available	Simple Western Validated Antibody	Western Blot Validated Antibody
GSK3	PT-65	7651			GSK-3 beta NBP1-47470
					Alpha/beta-AF2157
hCAII	hCAII Degrader 11	7964			
HDAC	HDAC4 CHDI Degrader 11	7882		NBP2-22151	
	JPS016	8083			
	JPS036	8085	Y		
HER 2	HER 2 PROTAC® CH7C4	7886			
IAP	CST 626	8021			
IRAK1	JNJ 1013	8029	Y		
IRAK3	IRAK3 Degrader 23	7983			
JAK2	SJ 1008030	7675			NBP2-59451, AF2988
JAK2/3	SJ 10542	7727			Jak3-MAB4699
KRASG12C	LC 2	7420	Y		
LCK	SJ 11646	7721		AF3704, MAB37041	AF3704, MAB37041
LDH	MS 6105	8073			
MAGE-3	KL 465	8854			
MIF	MD13	7503	Y	AF-289-PB, MAB289	AF-289-PB, MAB289
Mitochondria	AUTAC4	7699			
Mpro	MPD 2	8802			
Multikinase	TL 12-186	6524	Y		
NAMPT	NAMPT PROTAC® A7	7842		AF4335, MAB40441	AF4335, MAB40441
NSD2	UNC 8732	8118			
	MS 159	8079			
p38 MAPK	NR 7h	7177		p38 a-AF8691	
	SJFδ	7267			
	SJFα	7268		P38 g-AF1347, MAB1347	
PARP1	SK 575	7583	Y	AF-600-NA, MAB8095	AF-600-NA, MAB8095
PRC1	MS 147	8077			
PRC2	UNC 6852	7816	Y		
PGDS	PROTAC® (H-PGDS)-7	8004			
PRMT5	MS 4322	8080			
SMARCA4	JQ dS-4	8152			
STING	STING Degrader SP23	8053	Y	AF6516, NBP3-18816	AF6516, NBP3-18816

TABLE 1
Protein Degraders Catalog (Continued)

Target Protein	Product Name	Catalog #	Negative Control Available	Simple Western Validated Antibody	Western Blot Validated Antibody
TBK1	TBK1 PROTAC® 3i	7259	Y	AF9934, NB100-56705	AF9934, NB100-56705
TRIM24	dTRIM 24	6607			
TRK	CG 428	7425	Y	AF1494, AF397	AF1494, AF397
USP7	CST 967	7801			
VHL	CM 11	6416	Y		
Wee1	ZNL 02-096	7240	Y		NBP1-33506

Mechanistic Controls for Degradation Development

It is important to validate the mechanism of action when developing a novel Degradation. This can be achieved using a variety of small molecule pharmacological inhibitors for different steps of the TPD pathway.




Figure 3. Schematic overview of the small molecule Degradation-mediated proteasomal degradation cascade, and inhibitors commonly used at different steps of the cascade.

To discuss potential licensing opportunities for Degradation and related products, please contact our licensing team by completing the form on this page: rndsystems.com/about/partnerships-licensing



Contact Our Licensing Team

Scan the QR code or visit rndsystems.com/about/partnerships-licensing

TAG Degradation Platform

Tag, Degrade, Discover

The **TAG Degradation Platforms** (dTAG, aTAG and BromoTag®) are TPD based approaches to target validation that use a heterobifunctional Degradation targeting a TAG domain that is expressed as a fusion with a POI. This technology allows rapid and highly selective degradation

of a POI, without the requirement of developing a specific Degradation for each target protein, and offers a valuable approach to validate targets for which there is no known ligand. The technology is generalizable to a range of fusion proteins.

FIGURE 4




Figure 4. Schematic showing the mode of action of dTAG/aTAG /BromoTag Degradation. A POI is expressed as a fusion with a "TAG" protein. For the dTAG system the protein of interest is tagged with single-point mutant FKBP12 (F36V); the aTAG system uses MTH1 as the TAG; and the BromoTag system utilizes the TAG domain Brd4BD2 L387A. The TAG Degradation, which comprises a ligand that selectively binds the TAG protein linked to an E3 ubiquitin ligase ligand, initiates the formation of a ternary complex between an E3 ubiquitin ligase and the fusion protein which results in polyubiquitination of the target protein, its recognition by the proteasome and subsequent degradation of the entire fusion protein. dTAG/aTAG /BromoTag molecules act catalytically, repeatedly engaging and directing the ubiquitination of target molecules.

TAG Degradation is a promising alternative to genetic methods for target validation and can be used in cell culture or in vivo. The table below provides a comparison of TAG Degradation with commonly used genetic knockout/ knockdown approaches.

TABLE 2

TAG Degradation

	Dose Tuneability	Efficacy	Reversibility	Kinetics	Selectivity
TAG Degradation Platform (dTAG/aTAG/BromoTag)	***	****	****	***	****
Gene knockout e.g. CRISPR/Cas9	*	****	*	*	****
Gene knockdown e.g. RNAi	*	***	*	*	**

BromoTag® is a registered trademark of the University of Dundee and is used under license.

The R&D Systems product range offers several options for TAG Degradation, including dTAG, aTAG and BromoTag. The difference between them is the TAG protein. All can be used in vitro and in vivo and have the potential to be used in tandem.

TABLE 3
TAG Platform Product Listing

Platform	TAG Domain	TAG Degraders	Negative Controls	Related Products
dTAG	FKBP12 ^{F36V}	CRBN recruiting: dTAG-13 (Cat. No. 7259) dTAG-7 (Cat. No. 6912) dTAG-47 (Cat. No. 7530) VHL recruiting: dTAG ^V -1 (Cat. No. 6914) dTAG ^V -1 hydrochloride – Formulation of dTAG ^V -1 specifically for use in vivo (Cat. No. 7374)	dTAG-13-NEG (Cat. No. 6916) dTAG ^V -1-NEG (Cat. No. 6915) dTAG-47-NEG (Cat. No. 7531)	dTAG-Biotin (Cat. No. 7883) dTAG-Fluorescein (Cat. No. 7892) dTAG Janelia Fluor® 635 (Cat. No. 8101) dTAG Janelia Fluor® 525 (Cat. No. 8102) dTAG Janelia Fluor® 585 (Cat. No. 8103)
aTAG	MTH1	CRBN recruiting: aTAG 2139 (Cat. No. 6970) aTAG 4531 (Cat. No. 6971)	aTAG 2139-NEG (Cat. No. 7575)	
BromoTag	Brd4 ^{BD2 L387A}	VHL recruiting: BromoTag® AGB1 (Cat. No. 7686) BromoTag® AGB3 (Cat. No. 7688)	BromoTag® cis-AGB1 (Cat. No. 7687)	Polyclonal antibody (Cat. No. NBP3-17999)
AID2	OsTIR1 ^{F74G}	Skp 1 recruiting: 5-Ph-IAA (Cat. No. 7392) 5-Ph-IAA-AM (Cat. No. 7893)		
SNAP-tag	AGT	VHL Recruiting: VHL-SNAP2-5C (Cat. No 8890) CRBN5-SNAP2-1C-PIP (Cat. No. 8891)		
Other	Brd4 ^{BD1 L94V}	CRBN recruiting: XY-06-007 (Cat. No. 7669)		

FIGURE 5
Featured Product: dTAG Janelia Fluor® Probes

A range of fluorogenic srTAG probes for live cell imaging of FBKP12 (F36V/L) labeled proteins. dTAG Janelia Fluor® 525 (Cat. No. 8102), dTAG Janelia Fluor® 585 (Cat. No. 8103), dTAG Janelia Fluor® 635 (Cat. No. 8101).




Figure 5. HEK293 cells were incubated for 1 hour with 2.5 µM dTAG Janelia Fluor® 635 (red) and Hoechst (blue), without (left) or with (right) endogenous protein of interest labeled with dTAG/FKBP12^{F36V}. Fluorescent microscopy images kindly provided by Yongli Shan, Vincinitas Therapeutics.

TAG fusion proteins can be generated using genome engineering techniques such as transgene expression or CRISPR-Cas9-mediated locus-specific knock-in. See individual product listings for plasmid availability/CRISPR protocol.

FIGURE 6
BromoTag® AGB1 (Cat. No. 7686)

A highly selective and potent “Bump & Hole” TAG Degradator (DC_{50, 6h} 6h < 15nM).




Figure 6. (Top) Dose-response curve of BromoTag-Brd2 expression upon a 6 h treatment of AGB1. (Bottom) Western blot titration of AGB1 treated heterozygous BromoTag-Brd2 HEK293 cells.


BromoCatch™ Self Labeling Protein Tag Platform

BromoCatch is a next-generation self-labeling protein (SLP) tag platform for efficient protein analysis and live cell imaging. The new SLP tag platform offers:

- Minimal perturbation (less steric hindrance, less functional perturbation of the protein-of-interest)
- Orthogonal SLP platform that can be used with other legacy systems
- One-construct with broad application range (fluorescent imaging, affinity pull down, bio-orthogonal chemistry, targeted degradation, bioconjugations, assay development)
- Can be used for biochemical assays and live cell experiments
- Suitable for FRET assays for studying protein-protein interactions

TABLE 4
BromoCatch Product Listing

Product Name	Catalog #
BromoCatch™ Ligand, Alkyne	8940
Biotin BromoCatch™ Ligand	8939
Janelia Fluor® 635, BromoCatch™ Ligand	8937
Janelia Fluor® 525, BromoCatch™ Ligand	8997
Janelia Fluor® 585, BromoCatch™ Ligand	8998
BromoCatch™ Control Ligand	7300
Janelia Fluor® 549, BromoCatch™ Ligand	8942



Degrader Design & Synthesis

Develop Your Degraders with Our Toolbox of Functionalized Building Blocks

The R&D Systems Degrader product range supplies off-the-shelf chemical building blocks (functionalized E3 ligase ligands plus linkers) to enable researchers to develop their own Degraders. Our Degrader components have functional handles for easy conjugation to ligands/linkers of interest. The range includes the most effective and commonly used E3 ubiquitin ligase ligands, functionalized at positions known not to interfere with binding affinity. E3 ligase ligands conjugated to common linker groups are also supplied. The spectrum of Degrader building blocks that we offer is summarized below and in Figure 7.

Conjugation Functionality

Amine, Carboxylic acid, Azide, Alkyne, Alcohol

Linkers are functionalized with a reactive chemical ‘handle’ to enable coupling to your target ligand of interest.

E3 Ligase Ligand

A range of ligands are available for the most commonly recruited E3 ligases for TPD.

TABLE 5

E3 Ligases	Ligand
CRBN	Pomalidomide Thalidomide (4' and 5') Lenalidomide PG PD tDHU
VHL	VH 032 VH 101
IAP	A 410099.1 LCL 161 CST 530
L3MBTL3	UNC 1215

Negative control ligands available.

E3 Ligase Exit Vector

The exit vector bridges the E3 ligand to the linker group. Degrader building blocks are available with different exit vectors at various positions on the E3 ligase ligand.

Linkers

Alkyl C2-C10, PEG1-PEG6,Rigid linkers

The choice and length of linker is critical for achieving optimal formation of the ternary complex. It is also a key determinant of the physiochemical properties of the final Degrader molecule. The majority of Degraders for proof-of-concept studies use either a PEG or alkyl linker, while introducing rigid linkers such as piperazines can potentially improve the properties of second-generation Degraders.

FIGURE 7




Figure 7. Example of Degrader building block available off-the-shelf.



Explore Full Range of Degrader Building Blocks
Scan the QR code or visit rndsistemas.com/target/degrader-building-blocks






Contact Us for Bulk Quantities
Scan the QR code or visit rndsistemas.com/services/custom-targeted-protein-degradation-services

Assays for Targeted Protein Degradation

Successful development of small molecule Degraders requires a set of assays that explore target engagement by the Degrader, ternary complex formation, target protein ubiquitination and degradation, as well as downstream effects of protein knockdown.

FIGURE 8

Assay Workflow for Degrader Development

Assays for Degrader Development		Available Reagents/ Platforms
	Target Engagement	Fluorescence polarization (FP), time-resolved fluorescence resonance energy transfer (TR-FRET): Amenable to high-throughput operation. Applied for determination of binary and ternary binding affinity
	Ternary Complex Formation	FP, TR-FRET: Amenable to high-throughput operation. Applied for determination of cooperativity of ternary complex formation
	Ubiquitination	In vitro ubiquitination: Useful assay for cell-free assessment of degrader ability to induce a functional ternary complex and subsequent ubiquitination
	Degradation	Automated, high-throughput capillary electrophoresis instruments for reliable and reproducible detection and quantification. Open platform allows development of assays for any protein of interest
	Pharmacological Effect	Cell viability and apoptosis assays, DNA damage CometAssay®, antibody arrays, in situ hybridization: Useful assays to quantify the downstream effects of target degradation in both cells and tissues


Featured Product: CoraFluor™ TR-FRET Reagents

CoraFluor™ 1 (Cat. No. 7920) and CoraFluor™ 2 (Cat. No. 7950) are terbium-based TR-FRET donors that emit wavelengths compatible with commonly used fluorescent acceptor dyes such as FAM or FITC, BODIPY® (BDY), Janelia Fluor® dyes, TMR, and Cyanine 5, making it easy to incorporate into ongoing Degrader screening assays.

Compared to existing TR-FRET donors, the CoraFluor fluorescence is brighter and more stable in biological media, enhancing sensitivity and data generation from biochemical assays. CoraFluor™ 1 exhibits excitation upon exposure to a 337 nm UV laser, whereas CoraFluor™ 2

is cell permeable and displays a red-shifted excitation wavelength, enhancing excitation efficiency at 365 nm and 405 nm. These attributes of CoraFluor™ 2 enable live cell assays to be carried out on a wide range of analytical instruments.

CoraFluor™ is now available pre-conjugated to R&D Systems antibodies.



Target Engagement & Ternary Complex Formation

FIGURE 9
CoraFluor™ TR-FRET Target Engagement Assay




Figure 9. CoraFluor™ TR-FRET target engagement assay.

FIGURE 10
CoraFluor™ TR-FRET Ternary Complex Assay




Figure 10. CoraFluor™ TR-FRET ternary complex assay.

TABLE 6

TR-FRET Donors	E3 Ligase TR-FRET Tracers	POI TR-FRET Tracers
7920 - CoraFluor™ 1, amine reactive	Cereblon 7633 - BDY FL Thalidomide 7288 - Thalidomide-Cyanine 5	Pan BET Bromodomain 7722 - JQ1-FITC
7950 - CoraFluor™ 2, amine reactive	VHL 7483 - BDY FL VH032	PARP 6461 - PARPi-FL
8117 - CoraFluor™ 1, thiol reactive 8817 - CoraFluor™ 1, Haloalkane 8818 - CoraFluor™ 2, Haloalkane	IAP 8069 - XIAP Tracer mF-Smac	Pan Kinase 7985 - BDY FL Staurosporine

TR-FRET donors and tracers.

Simple Western: A Step Beyond Traditional Western Blots

The efficacy of Degradator molecules is generally characterized by generating dose-response curves using traditional SDS-PAGE Western blotting methods. This manual technique is lengthy and often has poor reproducibility, making it an unreliable approach for the determination of DC_{50} and D_{max} values. In contrast, **Simple Western™ instruments** automate the entire protein separation and detection process, enabling you to separate and analyze proteins by size (or charge) from 2 kDa to 440 kDa. You can analyze up to 96 samples in just 3 hours. You'll get quantitative results, reproducibility that's spot on, and use less sample in the process.

Simple Western systems are open platforms, meaning the possibilities are almost endless when selecting antibodies to develop your TPD assays. The **Simple Western Antibody Database** contains thousands of antibodies validated for Simple Western. The antibody database is curated to facilitate the selection process by providing general assay development guidance for identifying and selecting antibodies to test, saving you time with recommended starting points to optimize your TPD assays. You may also validate a new antibody and receive a free Separation or Detection Module to run your TPD assays on Simple Western. Learn more about our **Antibody Validation Promotion**.




Figure 11. Simple Western data showing dose response by treatment with ARCC 4 (Cat. # 7254) and ARCC 4 negative control (Cat. # 7255) in MDA-MB-453 cells. (A) Lane view showing AR degradation by ARCC 4 and ARCC 4 negative control measured on Leo. (B) Quantitation of AR peak area and DC_{50} values. All values are normalized to total protein measured in the same sample capillaries using RePlex. Values represent averages of all biological and technical replicates (n = 6) measured in a single Leo run (96 samples total). Error bars represent standard deviations from the means.

Explore Simple Western

Scan the QR code or visit rndsystems.com/instruments/simple-western

Simple Western Instruments

Jess™ System

- ✓ Size-based automated capillary Western assays
- ✓ Up to 25 capillaries per run
- ✓ Includes RePlex™ assay
- ✓ Chemiluminescence and fluorescence detection

Abby™ System

- ✓ Size-based automated capillary Western assays
- ✓ Up to 25 samples per run
- ✓ Includes RePlex™ assay
- ✓ Chemiluminescence detection

Leo™ System

- ✓ Size-based automated capillary Western assays
- ✓ Up to 100 capillaries per run
- ✓ Includes RePlex™ assay
- ✓ Chemiluminescence and fluorescence detection

Leo System



Rachel Doidge PhD,
Senior Research Scientist, Charnwood
Discovery, Biocity, Nottingham, UK



I work for a fast-paced drug discovery CRO where our clients expect high-quality data with rapid turnarounds. Jess allows me to accurately assess drug compound potency, and with its high throughput ability I can screen multiple compounds quickly and efficiently.

See How Your Peers Are Using Simple Westerns to Analyze Protein Knockdown by Targeted Protein Degradation

Charnwood Discovery is a UK-based Contract Research Organization involved in preclinical drug discovery. Specializing in custom assay development and applying new technological approaches to solve their clients’ project needs, the company has recently been running screening studies for PROTAC Degraders. Western blot analysis is the standard method for measuring protein levels and Degradar activity. Using traditional western blot, it was taking the Aurelia team 24 to 48 hours to get results. To improve their protein assays for drug discovery, the company now uses Simple Western on Jess. With Jess, the assay throughput time is faster, with the preparation time being 2-3x quicker than by traditional western blot and results are available in around 3 hours. In addition, Simple Western results are clear and easy to interpret.



Learn How Simple Westerns are Being Used in Targeted Protein Degradation
Scan the QR code or visit
learn.rndsystems.com/simple-western



Leo automates the protein separation and immunodetection of traditional Western blotting, eliminating many tedious, error-prone steps. Just load your samples and reagents into the microplate, and Leo separates your proteins by size and precisely manages antibody additions, incubations, washes, and even the detection steps. Come back to fully analyzed results in as little as 3 hours. Also, the **RePlex** feature enables you to run two immunoassays within the same capillary to get more rich protein characterization data from just one sample.

- Save your previous samples-only 3µl sample / well.
- Maximize data from your samples with chemiluminescence and fluorescence detection channels, RePlex and Resampling feature.
- Flexible normalization options with housekeeping proteins or built in total protein normalization.
- Confidence in data with highly precise and reproducible measurements.

Proteins for in vitro Ubiquitination Assays

R&D Systems proteins is the leading global provider of Ubiquitin Proteasome System (UPS)-related research products. Our superior quality proteins enable construction of assays to investigate in vitro ubiquitination of substrate proteins. This is a powerful approach to evaluate whether a target protein is ubiquitinated in the presence of a Degradar molecule and is amenable to both supplemented cell lysates and fully defined recombinant reactions. These assays provide a useful metric for Degradar discovery programs, without complicating factors such as Degradar cellular permeability and efflux.

In the example below, a functional CRBN E3 ligase complex (Cat. No. E3-650) was used to investigate in vitro polyubiquitination of recombinant FLAG-tagged BRD4 (Cat. No. SP-600). Results were analyzed using an anti-FLAG Western Blot.

Go to rndsystems.com to search the range of UPS-related products.

FIGURE 12
Degradar-dependent Polyubiquitination of Recombinant BRD4




Figure 12. Western blot data (left panel) and Simple Western data (right panel) showing Degradar-dependent polyubiquitination of recombinant BRD4. The degree of substrate ubiquitination varies with the concentration of Degradar used in the reaction, and the so-called “hook effect” is clearly evident.

TABLE 7

Products for in vitro Ubiquitination Assays

Assay Component	Product Name	Catalog #
ATP	ATP Disodium Salt	3245
BRD4 Substrate	Human His10-FLAG-BRD4 (49-460)	SP-600
Degrader	AKE-212	-
E1 enzyme	Human UBE1	E-304
E2 enzyme	Human UBE2D1	E2-616
E3 Ligase Complex	Human CUL4/RBX1/DDB1/CRBN	E3-650
Ubiquitin	Human Ubiquitin	U-100H

How Has This Degrader Affected My Cells?

Exploring the resulting phenotype following successful Degrader-mediated protein degradation enables an understanding of the biological role of the POI. A relevant question to ask is: “does degradation offer a more desirable or differentiated phenotype compared to inhibition?” Our downstream pharmacology assays provide researchers with methods to explore and understand the biological consequences of targeted protein degradation.

The R&D Systems brand offers a variety of assays to profile the downstream cellular response upon treatment with a Degrader.

Cell Viability and Proliferation Assays

Assessing cell viability and proliferation of a cell population upon treatment with a Degrader can be used to evaluate the toxicity or effectiveness of a series of candidate Degraders.



Featured Product:
Cell Counting Kit-8

Cat. No. 7368

Ready-to-use solution for high throughput cell viability and proliferation assays.

Apoptosis Assays

Measuring apoptosis using our [Annexin V-FITC Apoptosis Detection Kit](#) after treatment with a PROTAC is essential to assess the therapeutic efficacy, safety, and mechanism of action. By detecting apoptotic cells, it is possible to quantify the extent of cell death induced by PROTAC-mediated targeted protein degradation. This information helps optimize treatment conditions, differentiate apoptosis from necrosis, and identify potential off-target effects, ensuring a comprehensive understanding of the product’s impact on targeted cells. The Annexin V-FITC Apoptosis Detection Kit serves as a reliable tool for evaluating PROTAC performance and guiding their successful development for clinical applications.

TABLE 8

Cell Proliferation Assay Products

Product Name	Catalog #
TACS MTT Cell Proliferation Assay	4890-050-K
TACS XTT Cell Proliferation Assay	4891-025-K
Resazurin	AR002
Calcein AM	4892-010-01

DNA Damage CometAssay

Targeting undruggable proteins such as transcription factors is one of the promises of Degraders as new therapeutics. Degradation of targets such as BRD4 has cytotoxic effects and can interfere with transcription, resulting in DNA damage. [CometAssay Single Cell Gel Electrophoresis Assay](#) is able to characterise and quantify DNA double strand breaks following Degrader treatment, demonstrated in Figure 13 by treatment of HeLa cells with dBET6.

FIGURE 13




Figure 13. Single cell electrophoresis CometAssay to measure DNA double strand breaks after dBET6 treatment in HeLa Cells (6 hr dBET6 treatment at 10 nM).



Data provided by the Floyd Lab, Duke University

Proteome Profiler

[Proteome Profiler Antibody Arrays](#) are a simple, high throughput and cost-effective tool for early-stage analyte profiling and screening of up to 100 analytes in a single sample. Our antibody arrays have superior specificity, low background noise and no cross-reactivity, meaning that you can count on this assay for clear and consistent data. Use our antibody arrays as part of your PROTAC® assay cascade to explore the downstream consequences of Degrader-induced protein knockdown.

Spatial Insights with RNAscope™

[RNAscope™](#) in situ hybridization delivers high-sensitivity, single-molecule spatial detection of RNA within intact tissue, enabling precise mapping of gene expression changes driven by targeted protein degradation. Quantify low-abundance transcripts, splice variants, and pathway biomarkers with [multiplex fluorescent assay](#), same-section RNA-protein co-detection using protease-free [multiomic](#) workflows or using [ProximityScope™](#) technology to visualize functional protein interaction to inform pathway engagement in tissue context. Extensive peer-reviewed publications demonstrate robust performance across oncology, neuroscience, and translational models. Broad catalog and [custom probe](#) design support POIs, E3 ligases, ubiquitination pathway components, and downstream effectors. Apply RNAscope to validate mechanism of action, assess on-target vs off-target biology, and spatially resolve pharmacodynamic responses.



Induced Proximity Tools

Induced proximity is a field that is attracting increasing attention in the drug discovery field. Utilizing heterobifunctional and monovalent approaches, this technology extends beyond the ubiquitin proteasome system and offers new opportunities for targeted modulation, stabilization, post-translational modification, and inactivation/activation modalities.


Navigating the uncharted territory of induced proximity presents considerable challenges, including persisting knowledge gaps in validating novel mechanisms of action, accessing diverse chemical matter, and designing selective and potent small molecules and biologics for novel target spaces. The R&D Systems portfolio offers a range of products and services to support researchers in this exciting and rapidly evolving field.

Protein dimerizers, also known as chemical inducers of dimerization (CIDs), are chemical compounds which bind two different proteins and bring them into close proximity solely in the presence of the dimerizer.


TABLE 9
Protein Dimerizers Product Listing

Product Name	Catalog #	Product Action
Rapamycin	1292	mTOR inhibitor; immunosuppressant
AP 1903	6130	Chemical inducer of protein dimerization; active in vivo
NICE 01	8088	Heterobifunctional compound for nuclear import of FKBP ^{F36V} tagged proteins
AP 20187	6297	Chemical inducer of protein dimerization; active in vivo
Mandi	7681	Highly efficient chemical inducer of proximity (CIP)
TRAM 1	8121	Chemical inducer of proximity for dTAG protein FKBP ^{F36V} and ecDHFR tags
HaXS8	4991	Chemical dimerizer
Auxin	6834	Chemical dimerizer used in auxin-inducible degron (AID) system
XIE62-1004	7878	Inducer of autophagy via interaction of p62 and LC3

Featured Product: MolBoolean Kits



The MolBoolean™ Mouse/Rabbit Assay Kit (**Cat. No. MolB00001**) is a state-of-the-art tool for analyzing protein proximity within cells and tissues using advanced immunofluorescent detection. Specifically designed to quantify the levels of proteins A, B, and their interactions (AB), this kit works with user-selected mouse and rabbit primary antibodies and includes all necessary reagents for approximately 120 assays, following the provided protocol.





Quality that
you can trust
to drive your
innovations
forward.



R&D systems™ by biotechne

For Research Use or Manufacturing Purposes Only.

R&D Systems™ and Bio-Techne® are trademarks or registered trademarks of Bio-Techne Corporation and affiliated entities. All other trademarks, service marks, and trade names are the property of their respective owners. Any use of third-party names, logos, or marks does not imply affiliation, sponsorship, or endorsement. © 2026 Bio-Techne.

21121.0.0526